Truist reiterates Hold on Hims and Hers stock, $32 target
Truist Securities reiterated a Hold rating on Hims and Hers Health (HIMS) with a $32 price target. The stock is down 29% year-to-date. Q3 2026 results showed a subscriber decline due to reduced marketing spend, but revenue grew 49% YoY to $890.4M. Gross margins faced pressure, but the company remains optimistic about international growth and subscriber reacceleration in Q1 2027.
How this was made
The 30-second read
Why it matters
The earnings miss and lowered guidance prompted Truist to maintain a Hold rating and a $32 price target, suggesting limited upside.
Market read
Earnings miss and subscriber loss likely keep HIMS under pressure in the near term.
What to watch
Partnerships with Eli Lilly and Novo Nordisk may unlock future upside not reflected in the current earnings.
Background
Hims & Hers Health (NYSE:HIMS) reported Q3 2026 results with a 49% YoY revenue increase but a loss per share and subscriber decline.
Ticker impact
Truist reiterated Hold on Hims & Hers with a $32 target after the company posted Q3 2026 results showing subscriber loss, margin pressure and a miss on profit expectations.
downward pressure as the market prices in the profit miss and subscriber decline.
The earnings release includes a loss of $0.14 EPS and reduced subscriber count, prompting analysts to cut price targets.
Market effects
Telehealth sector may face broader scrutiny over subscriber growth and margin pressures.
U.S. telehealth stocks could see modest downside.
Limited to health‑tech investors; no broad market effect.
Counterpoint
If international revenue growth accelerates, the stock could rebound despite short‑term earnings weakness.
Key entities
- analystTruist Securities
Maintained Hold rating and $32 price target on HIMS.
- partnerEli Lilly
New partnership announced with HIMS.
- partnerNovo Nordisk
Expanded relationship with HIMS.
